Zydus Deflazacort Approved by FDA 424 Approvals Achieved
Indian pharmaceutical company Zydus Lifesciences has received final approval from the US Food and Drug Administration (US FDA) for Jaythari (Deflazacort) tablets. The drug is indicated for treating Duchenne Muscular Dystrophy (DMD) in patients 5 years and older, a rare and severe central nervous system disorder.
Deflazacort, a corticosteroid, is a reference-listed equivalent of Emflaza, providing an alternative for managing DMD. The tablets will be manufactured at Zydus’s Italy-based Doppel Farmaceutici facility, ensuring global standards in production.
This milestone brings Zydus’s total US FDA approvals to 424, out of 492 ANDAs filed since 2003-04. The approval signals another step forward for Zydus in addressing rare diseases and expanding its global footprint.
You May Interested In
2026-07-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Slams Door on Chinese Food Exports: Inspection Refusals Trigger Automatic Detentions
-
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
-
Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy
-
Four Fine Chemical Units of Huajin Aramco Project – HDPE, EO/EG, etc. – Reach Mechanical Completion
-
关于将二氟乙咪酯等16种物质列入《非药用类麻醉药品和精神药品目录》的公告 Announcement on the Inclusion of 16 Substances including Difluoroetomidate in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
EU Biocidal Data Protection Extension Raises the Stakes for Chemical Market Entry
-
Sudden Turmoil in Middle East Shipping Routes: Multiple Carriers Announce Emergency Navigation and Surcharge Policies
-
Your Plant Has the Data. Your AI Cannot Reach It. Here Is Why That Is the Core Problem in Chemical Manufacturing.
-
FDA Dye Pledges Push Natural Colors Into the Mainstream
Recommend Reading
-
FDA approves bemotrizinol, a long-used UV filter, for U.S. sunscreens
-
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
WACKER’s 2025 Loss Reaches €805 Million as the PACE Cost-Cutting Plan Becomes the Key Variable for 2026
-
关于加强防范钓鱼邮件的通知 Notification on Strengthening Anti-Phishing Measures
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
Methanol market prices rise significantly in China
-
Ethanol Market Prices Weakly Fluctuating
-
Ethylene Glycol Prices Recently Stop Declining—Beware of a Downward Spiral Triggered by a Sharp Drop in Crude Oil Prices
-
Insufficient cost support + weak demand: Melamine continues its weak consolidation
-
Supply Contraction Bottoming Out—PP Expected to Remain Stable with Slight Increase in Early June